NEW YORK (GenomeWeb) – BioMarker Strategies has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute to develop a companion diagnostic to identify head and neck squamous cell carcinoma (HNSCC) patients most likely to benefit from Erbitux (cetuximab).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.